Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka
- 283 Downloads
We conducted a retrospective collaborative investigation of bortezomib (Bor) plus dexamethasone (Dex) therapy (BD Tx) for 88 relapsed or refractory (Rel/Ref) MM patients at six institutes. One cycle BD Tx comprised of Bor (1.3 mg/m2/day) on days 1, 4, 8 and 11, and Dex on days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days, and the mean number of BD Tx cycles was 3. The overall response rate was 66.9%, the median overall survival (OS) was 510 days, and the median progression-free survival (PFS) was 113 days. Attainment of partial response (PR) with the first course of BD Tx associated with the longer OS and PFS and late good responder, while no patient who did not achieve PR with the first cycle attained better than very good PR (VGPR) with the subsequent BD Tx. Patient age of less than 64 years old also associated with the longer OS and PFS. In addition, both an earlier disease stage and Dex dosage had a significant impact on OS, while the attainment of VGPR within 2 cycles had a significantly longer PFS. Earlier BD Tx courses may be predictive for the subsequent therapeutic pathway of Rel/Ref MM.
KeywordsBortezomib Multiple myeloma Relapse
We wish to thank Drs K Taniguchi, Y Tsutsumi, M Yamamoto, N Sasaki, M Ohshiro, Y Shimura, S Mizutani and R Nakayama for their scientific support. This work was partly supported by the Award in Aki’s Memory from the International Myeloma Foundation (to J.K.).
- 9.Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143:537–40.PubMedGoogle Scholar
- 11.Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomised phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–901.CrossRefPubMedGoogle Scholar
- 13.Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau J, et al. Reversiblity of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of dose-modification guideline. Br J Haematol. 2009;144:895–903.CrossRefPubMedGoogle Scholar
- 15.Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan; a questionnaire-based report from the “lung injury by bortezomib” joint committee of the Japanese society of haematology and the Japanese society of clinical haematology. Int J Hematol. 2006;84:406–12.CrossRefPubMedGoogle Scholar
- 21.Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, et al. A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression. Int J Hematol. 2009;89:342–7.CrossRefPubMedGoogle Scholar